European drug regulator rejects Eisai and Biogen’s Alzheimer’s drug Leqembi, citing safety concernsnews2024-07-26T11:23:48+00:00July 26th, 2024|Endpoints News|
Calliditas claims mid-stage win for rare liver disease drugnews2024-07-26T11:15:36+00:00July 26th, 2024|Endpoints News|
FDA approves Sun Pharma’s JAK inhibitor Leqselvi for hair loss in adultsnews2024-07-26T11:00:16+00:00July 26th, 2024|Endpoints News|
Westlake’s non-opioid pain startup Latigo gets new leader; Ron Cooper lands next CEO gig at enGenenews2024-07-26T11:00:07+00:00July 26th, 2024|Endpoints News|
With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps anothernews2024-07-26T10:59:43+00:00July 26th, 2024|Endpoints News|
FDA advisors call for better studies of immunotherapy around lung cancer surgery, but give AstraZeneca a passnews2024-07-25T19:31:28+00:00July 25th, 2024|Endpoints News|
EU panel follows FDA’s lead on Wegovy, recommending use to prevent cardiac eventsnews2024-07-25T19:15:12+00:00July 25th, 2024|Endpoints News|
Ipsen loses legal appeal over whether blockbuster cancer treatment is a drug or biologicnews2024-07-25T18:11:18+00:00July 25th, 2024|Endpoints News|
Taking advantage of recent successes, Roche will push obesity drugs faster, flirts with M&Anews2024-07-25T17:51:42+00:00July 25th, 2024|Endpoints News|
AbbVie beats expectations with smaller Humira slide — and big gains for next autoimmune blockbustersnews2024-07-25T17:29:44+00:00July 25th, 2024|Endpoints News|